BLCO vs COO: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: COO is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BLCO and COO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BLCO and COO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Bausch + Lomb is one of the oldest and best-known names in eye health, operating across three segments: Vision Care (roughly 57% of sales, spanning contact lenses like Biotrue and lens-care solutions plus consumer eye drops such as LUMIFY and PreserVision supplements), Pharmaceuticals (around 25%, led by the dry-eye drug MIEBO and international brands), and Surgical (about 18%, including intraocular lenses, phacoemulsification systems and cataract and retina instruments). Full-year 2025 revenue reached roughly $5.1 billion, trailing twelve-month revenue is now about $5.3 billion, and the company sells into the structurally growing markets of an aging population, rising myopia and expanding cataract volumes.

Full BLCO guide

The Cooper Companies, headquartered in San Ramon, California and employing roughly ~15,000 people, has run on the same two-segment structure for years. CooperVision, about two thirds of revenue at ~$717.0M in the July 2026 quarter, makes soft contact lenses: daily disposables in silicone hydrogel, torics for astigmatism, multifocals for presbyopia, and MiSight 1 day, the only daily disposable lens with FDA approval to slow the progression of myopia in children. CooperSurgical, the other third at ~$349.2M, splits into fertility (IVF consumables, embryo culture media, cryostorage and genetic testing sold to fertility clinics) and an office and surgical line of devices sold into OB/GYN practices. The fiscal year ends October 31, so results labelled fiscal 2026 largely cover calendar 2026.

Full COO guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BLCO drivers: Margin and EBITDA expansion; Pharmaceuticals and MIEBO ramp.
• COO drivers: Myopia management and premium lens mix; Activist pressure and a possible breakup.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant overhang is Bausch Health's roughly $20 billion of consolidated debt and the repeatedly delayed separation, which caps BLCO's valuation and creates forced-seller and solvency-test risk. For COO, demand is the immediate problem: consumer weakness in Japan and China pushed CooperVision revenue in Asia-Pacific down ~6% earlier in the year, U.S.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BLCO if you believe its drivers more; COO if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BLCO and COO guides.

BLCO. BLCO is not yet GAAP-profitable, so investors lean on adjusted EBITDA, forward earnings and revenue growth rather than trailing multiples. At about 13 times EV/EBITDA, 15 times forward earnings and roughly 1.1 times sales, the stock trades below eye-care peers such as Alcon and The Cooper Companies, a gap that reflects the Bausch Health control discount, leverage and now a leadership transition. Q3 2026 results are due October 28, 2026, with consensus at about $1.37 billion of revenue and $0.22 of adjusted EPS, and the company has already signaled a guidance raise.

COO. GAAP and non-GAAP still diverge sharply, now in both directions: the trailing GAAP figure absorbs the ~$271.6M litigation charge and years of acquisition amortization but also a ~$307.2M U.K. tax benefit. On adjusted EPS guidance of ~$4.51 to ~$4.55, the shares at ~$58 trade near 12-13x, well below the multiple Cooper carried through most of the last decade, and 15 analysts hold a hold rating with a mean target near ~$65.80. The fiscal year closes October 31, and fourth-quarter guidance is ~$1.057B to ~$1.080B of revenue and ~$1.05 to ~$1.09 of adjusted EPS.

Headline figures (approximate, October 2026): BLCO shows revenue (ttm) ~$5.3B, revenue growth (q2 2026, yoy) ~9%, q2 2026 revenue ~$1.39B (adj. EPS $0.16 vs $0.16 est.), gross / operating margin ~61% / ~8%; COO shows revenue (ttm) ~$4.24B; July quarter up ~0.6%, fiscal 2026 revenue guidance (september) ~$4.229B to ~$4.252B, fiscal 2026 adjusted eps guidance ~$4.51 to ~$4.55, forward p/e ~12x at ~$58 per share.

BLCO and COO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BLCO and COO exposure against your real portfolio. It is not an investment adviser.